Kornimate/medical-research-clean huggingface dataset:
short-term working memory and executive training

Conditions: Psychotic Disorders

Summary: cognitive remediation (cr) therapies refer to a number of recent developments to use behavioural strategies to improve neurocognitive abilities and improve everyday functioning in mental disorders such as schizophrenia, bipolar disorder, and depression. in this study, we aim to examine whether we can observe cr effects on measures of neuroplasticity, cognition, and functioning when using a rigorous control comparison group. we hypothesize that the active group will exhibit improvements in executive functioning composite scores, improved eeg theta-gamma frequency modulation, and increased eeg alpha power compared to the placebo group.


Eligibility criteria:
inclusion criteria: * diagnosis of a chronic mental disorder (defined herein as bipolar disorder, major depressive disorder, or a schizophrenia-spectrum disorder) * between the ages of 18 and 65 * speak and read fluent english * able to use a computer exclusion criteria: * active substance abuse or dependence diagnosis * sensory or motor issues that would preclude completion of study procedures * enrollment in a cognitive remediation program or use of cognitive training programs (e.g. lumosity.com) within the past 6 months

Keywords: neurological disorders neuroscience neuropsychology eeg cognitive remediation cognitive response
assessment of transcutaneous oxygen tension/oxygen challenge test in intensive care unit (icu) patients

Conditions: Sepsis; Shock

Summary: the lack of subcutaneous partial pressure of oxygen (po2) rise in response to high fraction of inspired oxygen (fio2), called the "oxygen challenge test (oct)", was associated with higher morbidity and mortality in human subjects. patients had negative o2 challenge test results, indicating that flow-dependent o2 consumption might have been present. recent reports using the noninvasive transcutaneous po2 (pto2) and transcutaneous partial pressure of carbon dioxide probes have observed a relationship between low oxygen challenge test values to mortality and organ failure. the oct values provides an accessible noninvasive method of detecting early shock. to date,these studies of oct in the icu patients are rarely. no one has quantified oct to ci, do2i、scvo2. this study explored: 1. relationship between patient factors, hemodynamic variables, pto2, and oct to mortality; 2. relationship between pto2 index, tissue oxygen index, oxygen challenge index to ci, do2, scvo2.

pto2 index = pto2/pao2；tissue oxygen index=pto2/fio2； 5min oct value = challenged 5minpto2 - pto2baseline； 10min oct value= challenged 10minpto2- pto2baseline； oxygen challenge index = （10minpto2- pto2baseline）/(10minpao2-pao2baseline)

Eligibility criteria:
inclusion criteria: * 18 years of age or older * requiring a artery catheters, and pulmonary artery catheters or picco-plus or central venous catheters * fio2\ 92% * consent informed exclusion criteria: * not expected to live

Keywords: oxygen challenge test shock mortality oxygen delivery index cardiac output index
lifei xiaoji wan in treatment of advanced nsclc

Conditions: Advanced Non Small Cell Lung Cancer

Summary: this study is to evaluate the clinical efficacy of lifei xiaoji wan for advanced non-small cell lung cancer (nsclc), establish the treatment scheme, and obtain high-quality clinical evidence.

non-small cell lung cancer (nsclc) is a disease with high morbidity and mortality, poor prognosis, and a lack of safe and effective treatment. lifei xiaoji wan has significant advantages in the treatment of advanced nsclc, but the a lack of high-level clinical evaluation evidence and accurate mechanism of action research. according to the previous animal experiments of the team, it was proved that lifei xiaoji wan can significantly inhibit the tumor growth ability of lung cancer mice, and inhibit the proliferation, clonal formation, and migration ability of lung cancer cells. this topic intends to adopt the method of multicenter randomized controlled study to observe the lifei xiaoji wan for advanced nsclc patients' overall survival (os), progression-free survival (pfs), functional assessment of cancer therapy-lung (fact-l), tcm symptoms and syndrome and safety, help to clarify the role of lifei xiaoji wan in tcm prevention and treatment of lung cancer, can provide high-level evidence for tcm prevention and treatment of lung cancer research and clinical.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of nsclc. 2. the tumor stage (tnm) stage is from iii to iv. 3. 18-80 years old. 4. the expected survival period is\> 3 months. exclusion criteria: 1. early-stage patients with prior surgery and no recurrence. 2. patients with serious dysfunction of the heart, liver, heart, kidney, and other important organs. 3. mental illness and other patients were unable to complete the study.

Keywords: advanced non small cell lung cancer traditional chinese medicine randomized controlled trial
allosct for malignant and non-malignant hematologic diseases utilizing alpha/beta t cell and cd19+ b cell depletion

Conditions: Acute Leukemia; Severe Aplastic Anemia; Non-hodgkin Lymphoma; Hodgkin Lymphoma; Kostmann; Diamond Blackfan Anemia; Amegakaryocytic Thrombocytopenia; Sickle Cell Disease; Beta-Thalassemia

Summary: children, adolescents, and young adults with malignant and non-malignant conditionsundergoing an allogeneic stem cell transplantation (allosct) will have the stem cells selected utilizing α/β cd3+/cd19+ cell depletion. all other treatment is standard of care.

patients wiith selected malignant or non-malignant conditions meeting eligibility criteria will be enrolled on this study. patients will receive one of either full intensity, reduced intensity, or reduced toxicity conditioning appropriate based on disease, disease status, organ function and performance status and will undergo α/β t-cell and cd 19+ b cell depleted allosct. patients will be following for engraftment, chimerism, immune reconstitution, gvhd and qol.

Eligibility criteria:
inclusion criteria: 1. all:all high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (\<15% blasts at time of registration), mixed phenotype acute leukemia (mpal), persistent mrd (\<0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (44 chromosomes)) in first remission ' all in second remission and beyond; 2. aml: history of aml induction/reinduction failure (\<15% blasts at time of registration); aml in cr1 with poor cytogenetics (i.e. 12p, 5a, -7, flt3 mutation/duplication, t(9;11) and others); aml with persistent minimal residual disease (mrd) in cr1(\<0.01% on flow or persistent abnormal karyotype detected by cytogenetics); aml cr2 or beyond; aml in refractory relapse but ≤15% bone marrow leukemia blasts; therapy-related aml 3. high risk myelodysplastic syndrome (mds) 4 lymphoma: hodgkin (hl) or non-hodgkin (nhl): hl or nhl in induction failure; hl or nhl in pr1 or pr2 ; hl or nhl in cr2 or subsequent remission 5. bone marrow failure syndromes: kostmann syndrome refractory or intolerant to granulocyte colony-33stimulating factor; diamond-blackfan anemia refractory or intolerant to corticosteroids and/or cyclosporine'; amegakaryocytic thrombocytopenia 6. sickle cell disease (homozygous hemoglobin s disease, or hemoglobin s β 0/+ thalassemia, or hemoglobin sc disease) 7. age 0-30 years 8. adequate organ function exclusion criteria: 1. females who are pregnant or breast-feeding are not eligible. 2. patients with documented uncontrolled infection at the time of study entry are not eligible. 3. karnofsky/lansky (age appropriate) performance score \<60 4. demonstrated lack of compliance with medical care 5. patients who have received allogeneic hsct within 6 months, unless being done as a boost. 6. patients with active \<grade 2 gvhd.

Keywords: allogeneic stem cell transplantation t-cell depletion alpha beta cell depletion
implementation of the d-foot at the department of prosthetics and orthotics

Conditions: Diabetic Foot

Summary: early identification of potential risk factors for the onset of diabetic foot ulcers are recommended. however, in a swedish context, there has been no standardised routines to be used in the foot screening procedure. in this study a new standardised routine, the d-foot, will be tested at the department of prosthetics and orthotics. the usability of the web program will be tested.

the primary research questions are"how do patients with diabetes perceive the foot screening?" and "do the perception differ in the group that was foot screened by the use of the d-foot compared to the group that was foot screened with conventional methods?"

Eligibility criteria:
inclusion criteria: * diabetes * patients referred to the department of prosthetics and orthotics at sahlgrenska university hospital with the aim to be provided with assistive devices with the purpose to protect the feet from foot ulcers * be able to read and understand the swedish language exclusion criteria: \*being unable to read and understand the swedish language
effects of a 0.03% chx mouth rinse in peri-implant mucositis

Conditions: Peri-implant Mucositis

Summary: aim: to evaluate the efficacy of a 0.03% chlorhexidine (chx) and 0.05% cetyl pyridinium chloride (cpc) mouth rinse, as an adjunct to professionally and patient-administered mechanical plaque removal, in the treatment of peri-implant mucositis. material and methods: patients displaying peri-implant mucositis in, at least, one implant were included in this randomized, double-blinded, clinical trial. subjects received a conventional professional prophylaxis (at baseline and 6-month visits) and were instructed to regular oral hygiene practices and to rinse, twice daily, during one year, with a 0.03% chx and 0.05% cpc mouth rinse, or a placebo. clinical, radiographic and microbiological data were recorded at baseline, 6 and 12 months. disease resolution was defined as the absence of bleeding on probing (bop). repeated measures anova, student-t and chi square tests were used.


Eligibility criteria:
inclusion criteria: * the presence of, at least, one dental implant with clinical signs of peri-implant mucositis, defined as gently bleeding on probing (bop) and/or suppuration without progressive radiographic bone loss (after at least 1 year of functional loading) exclusion criteria: * untreated or recurrent periodontitis \[presence of nine or more sites with pd 5 mm and with full mouth bleeding score (fmbs) \> 25%\]; * implants affected by peri-implantitis, (bop and/or suppuration and progressive radiographic bone loss); * removable implant-retained prosthesis; * history of intake of systemic antibiotics within the previous month or other chronic systemic medications that could interfere with the study outcomes; * and women being pregnant or breast-feeding.

Keywords: peri-implant mucositis chlorhexidine cpc treatment
risk of cv events with efv vs. efv-free regimens

Conditions: HIV/AIDS

Summary: the purpose of this study is to determine whether there is an increased risk of cardiovascular events (cv) with regimens containing efavirenz (efv) versus other regimens in patients with hiv.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * aged 18 years or older on the index date * have at least one pharmacy claim for efavirenz or a drug in the comparison cohort during the period spanning january 1, 2007 through december 31,2013. * clinical modification (icd-9) diagnosis code for hiv infection including 042 (hiv disease), v08 (asymptomatic hiv infection status), 795.71 (nonspecific serologic evidence of hiv), and 079.53 (hiv, type 2) any time prior to the index claim. * have at least 6 months (180 days) of continuous enrollment prior to the index claim exclusion criteria: * patients who have been dispensed any antiretroviral medications anytime before the index date including the 180-day baseline period * patients with evidence of a cardiovascular outcome of interest during the 180-day baseline period
ayurvedic herbs in diarrhea predominant irritable bowel syndrome

Conditions: Irritable Bowel Syndrome

Summary: in the present study the investigators are trying to evaluate the effect of murraya koenigii leaves, punica granatum and curcuma which is administered to the patients in a combined form as tea. this study will help to evaluate the effect of these preparations scientifically in improving the ibs symptoms.

see above

Eligibility criteria:
inclusion criteria: * irritable bowel syndrome according to rom-iii * subtype diarrhea or alternating * discomfort or pain \> 1 times a week * discomfort or pain \> 4 on a visual analog scale exclusion criteria: * inflammatory bowel diseases (test results necessary) * lactose, fructose malabsorption (test results necessary) * celiac disease * pregnancy or breastfeeding * colectomy or hemicolectomy \>50cm * severe metabolic disorders, hormonal disorders, cardiac or respiratory failure, liver or renal diseases * severe depression, psychotic or psychiatric disorders, substance abuse * cancer within the last 5 years * allergy to caraway * acute inflammatory diseases
massage versus cold water immersion for fatigue-induced biomechanical alterations

Conditions: Running; Fatigue

Summary: the optimization of recovery to alleviate the effects of fatigue in athletes can provide valuable performance advantage. however, despite the growing body of literature regarding effects of different interventions in fatigue, there is still lack of clarity regarding the efficacy of interventions on running economy and, particularly, fatigue-induced biomechanical alterations. therefore, the aim of this study was to compare the effects of massage and cold water immersion for enhancing recovery and alleviating fatigue after an exhausting training session. we hypothesized that both massage and cold water immersion would enhance biomechanical parameters compared with a control condition and hence would improve subsequent running economy.

in this randomized controlled all the subjects (n=48) will performed the same protocol. the protocol will begin with a exhausting training session (20-min warm-up consisted of 15-min of continuous self-paced running followed by 5-min of fast-finish progression runs increasing speeds (from approximately 60% to 80% of maximal heart rate, participant controlled), 10 x 500 m sprints at 90% of maximal heart rate with a 2-min rest period between bouts and a recovery phase consisting of 10-min of slow jogging). twenty-four hours after this exhausting training, subjects will perform an incremental running test on a treadmill (pre-intervention test) where subjects will start at 12 km/h for 6 min after which speed will be increased by 2 km/h every 6 min until a 16 km/h trial is completed. at the end of each stage, participants will rate their perceived exertion using the 10-point modified borg rating of perceived exertion scale (rpe scale). one hour after this test, in one protocol subjects will receive the massage intervention, (massage group); other group will receive a cold water immersion intervention (cold water immersion group); in the other group (control group) participants will rest passively in a sitting position for 30-min period. to evaluate the relevance of the changes induced by the interventions (massage, cold water immersion, passive rest) subjects will repeat the treadmill test 48 hours after the first test (72 hours after the exhaustive training).

Eligibility criteria:
inclusion criteria: * recreationally active (current participation in races and a 10-km race time\<34.5-min) exclusion criteria: * suffered from any injury within the preceding 4 months.

Keywords: recovery intervention fatigue running cryotherapy running economy
adebrelimab combined with fluzoparib in hrd-positive hr +/her2- advanced breast cancer

Conditions: Female Breast Cancer Patients; Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer; HRD Positive Advanced Breast Cancer

Summary: this is an open-label, single-arm, exploratory study planned to include 40 patients with hrd-positive hr +/her2- advanced breast cancer treated with adebrelimab in combination with fluzoparib. to observe and evaluate the efficacy and safety of adebrelimab combined with fluzoparib in the treatment of hrd-positive hr +/her2-advanced breast cancer


Eligibility criteria:
inclusion criteria: 1. female breast cancer patients aged ≥ 18 years and ≤ 75 years; 2. histopathologically confirmed advanced hr +/her2-invasive breast cancer according to the latest asco/cap guidelines, meeting the following conditions: her2 negative: ihc 0/1 + or ihc2 + but ish negative; er positive: ihc ≥ 1%, pr positive: ihc ≥ 1% 3. ecog score 0 \~ 2; 4. in the treatment stage of recurrence and metastasis, ≤ 1 line of chemotherapy is allowed, at least ≥ 1 standard endocrine therapy (including cdk4/6 inhibitor therapy) is allowed, and ≤ 1 antibody-conjugated drug (adc) is allowed; 5. hrd positive confirmed, known germline and/or systemic brca mutation status and hrr pathway-related gene mutation status allow preferential enrollment; 6. appropriate level of organ function 7. patients voluntarily participate in and sign the informed consent form, are expected to have good compliance and cooperate with the study according to the requirements of the protocol. exclusion criteria: 1. active or symptomatic brain metastases systemic anticancer therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization) within 14 days prior to enrollment 2. patients previously received pd-1/pd-l1 antibody, ctla-4 antibody, or other treatments against pd-1/pd-l1 inhibitors; 3. female patients who are pregnant and lactating, female patients who are fertile and have a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial.4.have a clear history of neurological or psychiatric disorders, including epilepsy or dementia, and the subject has a known history of psychotropic drug abuse, alcoholism 5.human immunodeficiency virus (hiv) infection or known acquired immunodeficiency syndrome (aids); positive hepatitis b surface antigen (hbsag) test, or positive hepatitis b core antibody (hbcab) test followed by positive hbv-dna test (hbv-dna test was performed only in patients with negative hbsag test and positive hbcab test); positive hepatitis c virus (hcv) antibody test followed by positive hcv-rna test (hcv-rna test was performed only in patients with positive hcv antibody test) 6.any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.
femoral nerve block for analgesia after anterior cruciate ligament reconstruction

Conditions: Analgesia After ACL Reconstruction

Summary: femoral nerve block using 0.25% bupivacaine or 0.5% bupivacaine provides a longer time for analgesia after anterior cruciate ligament (acl) reconstruction.


Eligibility criteria:
inclusion criteria: * patients scheduled for acl reconstruction * asa physical status i-ii * body weight \> or = 50 kg. exclusion criteria: * patients with redo acl reconstruction * contraindication to neuraxial block * allergy to local anesthetics, sulfa, nsaids, morphine, paracetamol * patients with communication problem

Keywords: femoral nerve block
association between renal resistive index(rri) and aki(acute kidney injury) in cardiac surgery patients with cardiopulmonary bypass (cpb)

Conditions: Acute Kidney Injury; Renal Resistive Index

Summary: aki(acute kidney injury) is a common complication after cardiac surgery which is associated with increased mortality and morbidity. the conventiional marker for detecting aki is serum creatinine, however, which has many limits. rri(renal resistive index) is a non-invasive test measured by ultrasound and could be a useful tool to evaulate renal insult in the early phase. early detection of renal insult and prevention of progression to aki can contribute to reduing mortality and morbidity in cardiac surgical patients.


Eligibility criteria:
inclusion criteria: * aged 19 years and older scheduled for cardiac surgery using cpb exclusion criteria: * emergency opeartion, pre-operative shock status requiring vasopressor or inotropics, s/p kidney transplant patients, ckd stage 4 and 5 patients, patients who have renal artery stenosis or history of renal artery stent implantation, patients who have ascites with child-pugh classification b or c, in case of cpb weaning failure, in case of poor lung function and pao2 or paco2 cannot be maintained within normal range.
the pulmonary safety of antihepatitis c treatment

Conditions: Hepatitis C

Summary: pulmonary side effects of the new regimen of antihepatitis c

hepatitis c is a liver disease caused by the hepatitis c virus.the hepatitis c virus is a blood borne virus the most common modes of infection are through exposure to small quantities of blood, through injection drug use, unsafe injection practices, unsafe health care, and the transfusion of unscreened blood and blood products. an estimated 71 million people have chronic hepatitis c infection. a significant number of those who are chronically infected will develop cirrhosis and or liver cancer. the treatment of hepatitis c virus (hcv) infection has been difficult, particularly in patients with hcv genotype 1. reasons for the difficulty include the inherent toxicity and limited efficacy of interferon-based therapy, which has been the cornerstone of anti-hcv efforts during the past 2 decades. newly available direct-acting antiviral agents (daas) have the potential to dramatically improve hcv eradication rates. despite these new drugs has been characterized by a very low adverse events rate in the published clinical trials few data are available on pulmonary adverse events based real life studies

Eligibility criteria:
inclusion criteria: 1. hcv rna positivity . exclusion criteria: * child c cirrhosis. * clinically manifest liver decompensation :ascites ,encephalopathy, wasting, hepatorenal syndrome. * serum albumin less than 2.8 g/dl,total serum bilirubin more than 3 mg/dl ,inr1.7 or more . * absolute neutrophil counts \< 1500\\mm3 and\\or platelet less than 50,000/mm3. * hcc except 6 months after concluding intervention aiming at cure with no evidence of activity by dynamic ct or mri. * extrahepatic malignancy except after two years of disease\\disease free interval * in lymphomas and chronic lymphatic leukemia can be initiated immediately after remission based on the treating oncologist's report * pregnancy or inability to use effective contraception * inadequately controlled diabetes mellitus (hba1c\>9%) * sever renal impairment in which creatinine clearance \< 30 ml\\min * chronic lung diseases .